PL3067353T3 - Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania - Google Patents

Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania

Info

Publication number
PL3067353T3
PL3067353T3 PL16156678T PL16156678T PL3067353T3 PL 3067353 T3 PL3067353 T3 PL 3067353T3 PL 16156678 T PL16156678 T PL 16156678T PL 16156678 T PL16156678 T PL 16156678T PL 3067353 T3 PL3067353 T3 PL 3067353T3
Authority
PL
Poland
Prior art keywords
inclusion
preparation
dosage forms
pharmaceutical dosage
solifenacin
Prior art date
Application number
PL16156678T
Other languages
English (en)
Inventor
Milos Ruzic
Darja Prudic
Anica Pecavar
Antonio Zanotti-Gerosa
Tadej Stropnik
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of PL3067353T3 publication Critical patent/PL3067353T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
PL16156678T 2008-07-29 2009-07-29 Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania PL3067353T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SI200800188 2008-07-29
SI200800285 2008-11-20
SI200900113 2009-04-21
EP16156678.1A EP3067353B1 (en) 2008-07-29 2009-07-29 A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP09777523A EP2310387A2 (en) 2008-07-29 2009-07-29 A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
PL3067353T3 true PL3067353T3 (pl) 2018-04-30

Family

ID=41610777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16156678T PL3067353T3 (pl) 2008-07-29 2009-07-29 Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania

Country Status (5)

Country Link
EP (2) EP2310387A2 (pl)
HR (1) HRP20180150T1 (pl)
PL (1) PL3067353T3 (pl)
SI (1) SI3067353T1 (pl)
WO (1) WO2010012459A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023529B1 (ru) * 2009-02-27 2016-06-30 КРКА, д.д., НОВО МЕСТО Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
EP2415472A4 (en) * 2009-03-30 2013-02-20 Astellas Pharma Inc SOLID PHARMACEUTICAL COMPOSITION WITH SOLUBENACIN AMORPHIC BODY
EP2590973B1 (en) 2010-07-05 2016-08-31 Crystal Pharma, S.A.U. Solifenacin salts
EP2638039A1 (de) * 2010-11-11 2013-09-18 Hexal AG Kristallines solifenacin-succinat
EP2500013B1 (en) * 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
EP2778167A1 (en) * 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
JP2015189677A (ja) * 2014-03-27 2015-11-02 テバ製薬株式会社 ソリフェナシン非晶質体を含有する医薬組成物
CN112552237B (zh) * 2020-12-23 2022-10-14 中山奕安泰医药科技有限公司 索菲那新中间体的精制方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1879867A2 (en) 2005-12-21 2008-01-23 Teva Pharmaceutical Industries Ltd Intermediates for preparing solifenacin
EP2046751A4 (en) 2006-07-19 2010-12-29 Reddys Lab Ltd Dr PROCESS FOR PRODUCING SOLIFENACIN AND ITS SALTS
EP1943248A2 (en) 2006-08-03 2008-07-16 Teva Pharmaceutical Industries Ltd. Solifenacin base forms and preparation thereof
CZ300692B6 (cs) 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
EP2229387A1 (en) * 2007-12-04 2010-09-22 Cadila Healthcare Limited Process for preparing chemically and chirally pure solifenacin base and its salts

Also Published As

Publication number Publication date
EP3067353B1 (en) 2017-11-22
WO2010012459A2 (en) 2010-02-04
SI3067353T1 (en) 2018-03-30
WO2010012459A3 (en) 2010-08-05
EP2310387A2 (en) 2011-04-20
HRP20180150T1 (hr) 2018-03-09
EP3067353A1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
ZA201006029B (en) Pharmaceutical dosage form
PL3067353T3 (pl) Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
EP2429506A4 (en) DOSAGE FOR COATED PHARMACEUTICAL CAPSULES
EP2450046A4 (en) MEDICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF BRONCHITIS AND PREPARATION THEREOF
ZA201304709B (en) A pharmaceutical dosage form
ZA200906899B (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
IL219120A (en) Cyclohaphtha pyridinyl derivatives and their use in drug preparation
SI2400954T1 (sl) Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli
HUP1000069A2 (en) New salts for the preparation of pharmaceutical composition
SI2086945T1 (sl) Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
SI2588090T1 (sl) Trdne peroralne farmacevtske oblike, ki obsegajo dabigatran eteksilat in njegove farmacevtsko sprejemljive soli
TWI559929B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IL213502A (en) Use of agonist d1 / d2 compounds for drug preparation
ZA200903858B (en) Pharmaceutical dosage form
IL219617A0 (en) Pharmaceutical solid dosage form
SI2736909T1 (sl) Proces za pripravo sitagliptina in njegovih farmacevtsko sprejemljivih soli
SI2536396T1 (sl) Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
WO2011018801A3 (en) Solid oral dosage form of ziprasidone
EP2789334A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DIAMINODIPHENYLSULFONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH MUSCLE ATROPHY
HUP1000444A2 (en) Process for the preparation of a pharmaceutical active ingredient
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease